DiaMedica Therapeutics (DMAC) Common Equity (2017 - 2026)

DiaMedica Therapeutics (DMAC) has reported Common Equity for 10 consecutive years, with $38.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 41.1% year-over-year to $38.3 million; the trailing twelve-month figure through Jun 2026 stood at $38.3 million (up 41.1% YoY), and the FY2025 full-year result was $56.1 million, up 37.8% from the prior year.
• Common Equity retreated to $38.3 million in Q2 2026 per DMAC's latest filing, from $47.2 million in the prior quarter.
• Across five years, Common Equity topped out at $59.7 million in Q2 2023 and bottomed at $27.0 million in Q1 2023.
• Historically, Common Equity has averaged $43.4 million across 5 years, with a median of $43.6 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Common Equity surged 85.62% in 2022, then plunged 49.13% in 2025.
• Over 5 years, Common Equity stood at $31.8 million in 2022, then soared by 60.42% to $51.1 million in 2023, then decreased by 20.25% to $40.7 million in 2024, then surged by 37.8% to $56.1 million in 2025, then tumbled by 31.67% to $38.3 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $38.3 million, $47.2 million, and $56.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.